Maria Blasco

Blasco presents a durable and scientifically specific vision centered on targeting telomeres and telomerase to treat age-related disease and promote healthy aging. Proposed routes include telomerase gene therapy, telomerase reactivation for fibrosis, and young small-extracellular-vesicle treatment. However, the evidence does not show a clearly articulated destination for ending aging or materially extending human lifespan, nor timelines, clinical milestones, or sustained public advocacy for such an overarching goal.

Exceptional citation-weighted impact indicates field-defining influence in aging and telomere biology. An h-index of 117, more than 71,000 citations, and multiple foundational papers exceeding 1,000 citations demonstrate influence far beyond publication volume.

The supplied evidence documents substantial scientific activity but no deployment of investment or philanthropic capital. Scientific publications, citations, and awards do not make the capital_deployed dimension applicable.

No public capital deployment activity is evidenced; Maria Blasco is presented as a scientist, with zero investments or donations found.

Blasco’s sustained focus on telomeres and telomerase represents a coherent scientific thesis connecting aging, cancer, and regenerative capacity. Her highly cited mouse studies from the late 1990s suggest an early, productive commitment to this research direction. However, the evidence does not establish that these choices were contrarian, uniquely catalytic, or counterfactually decisive for the field, so a top-tier score is not justified.

Blasco contributed to field-building by locally organizing an international healthy-aging conference, but the evidence does not show that she created a new organization, program, category, community, protocol, or funding pathway.

The dimension is applicable, but the supplied evidence documents scientific productivity and recognition rather than public risk-taking or conviction. No evidence establishes a contrarian stance, career sacrifice, a personally significant bet, persistence under serious criticism, or self-experimentation.

Blasco demonstrates substantial scholarly multiplier effects: a large, highly cited body of work has influenced aging and telomere research well beyond her direct experiments, while multi-institutional publications indicate broad collaboration. However, the evidence does not establish comparable leverage through organization-building, capital deployment, policy influence, or founder formation.